Orphan Drug Approvals — July 24, 2026

AFT PHARMACEUTICALS LTD received a label expansion for SIROLIMUS (SCOMARA), a fallback approval with a bullish signal (strength 5/10, materiality 5/10), potentially expanding its orphan drug market reach.

SIROLIMUS faces competition from other mTOR inhibitors and generic sirolimus formulations, potentially limiting AFT PHARMACEUTICALS LTD's market share despite the label expansion.

Pricing power for SIROLIMUS (SCOMARA) is NOT_DISCLOSED, creating uncertainty about revenue potential and payer coverage for AFT PHARMACEUTICALS LTD.

The label expansion for SIROLIMUS (SCOMARA) could open a new patient population for AFT PHARMACEUTICALS LTD, potentially driving incremental revenue in a niche orphan drug market.

The single approval in this period is a label expansion for an existing orphan drug, SIROLIMUS, indicating ongoing lifecycle management rather than novel NME development in rare diseases.

{"entity"=>"SIROLIMUS (SCOMARA) by AFT PHARMACEUTICALS LTD", "reason"=>"Label expansion approval with undisclosed commercial details; execution risk remains.", "trigger"=>"Launch date, first-quarter sales data, and payer coverage decisions for the expanded indication"}